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Methods
Subjects
Enrolled in the present study were AHFS patients (including those with acutely decompensated chronic heart failure), who were hospitalized between July 2004 and March 2006 and did not receive "treatment B" as shown in Fig 1; all were scheduled to receive treatment with carperitide, and had: (1) systolic blood pressure (SBP) ≥120 mmHg; (2) evidence of pulmonary congestion on chest X-ray examination or auscultation; and (3) dyspnea in either rest state, during the performance of light work or at night. Excluded were patients with severe hypotension, cardiogenic shock, right ventricular myocardial infarction and dehydration. Apart from these patients, those who were otherwise assessed as unsuitable subjects for the present study were also excluded.
Study Protocol and Measurements
The study protocol is outlined in Fig 1. The present study was a prospective investigation of actual clinical practice, and patients were enrolled at the enrollment center. Prior medication by intravenous bolus injection including diuretics, nitrates, digoxin and morphine, or an additional bolus injection of intravenous diuretics was permitted. The dose of carperitide was adjusted according to the condition of each individual patient, and if symptoms of heart failure were not adequately improved by carperitide, concomitant use of or replacement with other agents indicated for the treatment of AHFS was permitted. In the present study, carperitide monotherapy was defined as the use of continuous intravenous infusion of carperitide alone, although concomitant use of "treatment A" as shown in Fig 1 was allowed. Patients who received carperitide plus "treatment B" or were switched from carperitide monotherapy (with or without concomitant "treatment A") to "treatment B" were defined as those receiving "non-carperitide monotherapy".
The severity of heart failure was classified according to New York Heart Association (NYHA) classification and Killip classification upon admission. Blood pressure, heart rate and clinical symptoms such as peripheral edema, rales, cold legs and elevated jugular venous pressure were assessed before the start of treatment and throughout the administration period. Furthermore, urine volume, chest X-ray and items determined by echocardiography such as left ventricular end-diastolic dimension, left ventricular end-systolic dimension, %FS, left ventricular ejection fraction (LVEF), tricuspid regurgitation pressure gradient, diameter of the inferior vena cava and degree of mitral regurgitation were determined in all subjects. Hemodynamic parameters were also assessed in subjects undergoing Swan -Ganz catheter examination. In patients whose red blood cell count, hemoglobin, hematocrit, serum creatinine and C-reactive protein (CRP) were determined upon admission, these values were also followed.
Recovery from acute phase of heart failure by carperitide monotherapy was determined by each investigator based on hemodynamics findings and clinical symptoms. In cases in whom the acute phase was not recovered by carperitide monotherapy, reasons were selected from: (1) insufficient efficacy of carperitide; (2) onset of adverse drug reactions (ADRs) of carperitide; and (3) other reasons.
To examine medication status, the type, dosage and duration of concomitant medications for the treatment of AHFS were recorded as well as the type of oral medications for the treatment of chronic heart failure. The degree of dyspnea was assessed by the modified Borg scale before and during treatment. 12 All adverse events were investigated and documented by type, appearance date, severity, outcome and causal relation with carperitide. Outcomes were assessed either when patients were discharged or at 1 month after Study protocol. After hospitalization, patients who were scheduled to receive treatment with continuous intravenous infusion of carperitide were enrolled. Prior to carperitide infusion, bolus injections of diuretics and/or nitrates ("treatment A") as well as oxygen administration were allowed. In those in whom the efficacy of carperitide was insufficient, repeated "treatment A" and concomitant use of or replacement with other agents for acute heart failure or mechanical aid ("treatment B") was allowed. Patients receiving "treatment A" alone were categorized as receiving "carperitide monotherapy". In contrast, those who concomitantly used or were switched to receive other agents indicated for acute heart failure as described in "treatment B" were not defined as receiving carperitide monotherapy. ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; PDE, phosphodiesterase.
completion of treatment with carperitide, whichever came earlier.
The present study was conducted according to international regulations for clinical study at each institution. Written or oral informed consent regarding medical treatment including carperitide therapy was obtained from each patient or the patient's family upon admission.
Statistics
Parametric data are presented as mean ± standard deviation. The difference in scores of the modified Borg scale at each time point from baseline was assessed using one-way repeated measures ANOVA. The recovery rate from acute phase among patients stratified using baseline characteristics was assessed using Fisher's exact test. Patients classified into 4 categories according to the criteria of Nohria et al were analyzed and compared for recovery rate using the chi-square test. 13 ADRs in patients stratified by baseline characteristics were analyzed by Fisher's exact test. The 2-sided significance level was 5% for all tests.
Results
Patient Enrollment
In the present study, 1,932 patients from 299 medical institutions were enrolled. Among these patients, 100 were excluded: 92 patients failed the exclusion criteria, 5 were excluded because of double enrollment and 3 were excluded for other reasons. Thus a total of 1,832 patients were eligible for the present study and included in the analysis set for efficacy and safety assessments.
Baseline Characteristics
Among the 1,832 patients studied, 965 (52.7%) were male. The mean age was 75.1±12.7 years and elderly patients aged ≥80 years accounted for 42.0%. The analysis set consisted of 1,136 patients (62.0%) with acutely decompensated chronic heart failure and 696 patients (38.0%) with the first onset of AHFS. Underlying heart diseases were valvular heart disease in 578 patients (31.6%), hypertensive heart disease in 537 patients (29.3%), old myocardial infarction in 408 patients (22.3%) and acute myocardial infarction in 79 patients (4.3%). Complications included renal disease in 467 patients (25.5%) and pneumonia in 215 patients (11.7%). The severity of heart failure was NYHA functional class III-IV in 1,445 patients (78.8%).
After admission, the following medications by intravenous bolus injection were given prior to carperitide: diuretics in 835 patients (45.6%); nitrates in 73 (4.0%); digoxin in 70 (3.8%); and morphine hydrochloride in 20 (1.1%; Table 1 ). Mean SBP was 151.1±25.7 mmHg on admission. Patients maintained relatively adequate myocardial contractility, with mean LVEF 45.5±17.3%. Mean serum creatinine level was 1.3±1.4 mg/dl on admission (Table 2) . 
Carperitide Dosing and Administration
The initial dosage of carperitide was ≤0.0125, >0.0125-0.025, and >0.025-0.05 g·kg -1 ·min -1 in 10.7%, 21.1%, and 50.4% of patients, respectively. Treatment with carperitide was started at a low dose then either increased or decreased according to the condition and blood pressure of each individual patient. The mean duration of treatment with carperitide was 5.2±4.8 days, and treatment was completed within 1 week in 78.8% of patients.
Efficacy
Treatment of AHFS using carperitide monotherapy achieved recovery of the acute phase to the chronic phase in 1,524 of 1,832 patients (83.2%). Among the remaining 308 patients (16.8%) who did not recover from the acute phase by carperitide monotherapy, 225 patients underwent concomitant or alternative medications and/or mechanical support for inadequate response: inotropic agents were given to 95 patients (42.2%) and vasodilators (mainly nitrates) to 66 patients (29.3%; Fig 2) . Of the 95 patients who were treated with inotropic agents, 20 received phosphodiesterase inhibitors.
Among the 1,524 patients who recovered from the acute phase using carperitide monotherapy, 1,513 were assessed for the degree of dyspnea using a modified Borg scale. The mean score before the start of treatment with carperitide was 5.98±2.50 ("strong" to "very strong"). After treatment for 2 h, the mean score was significantly decreased to 3.73± 2.15. After treatment for 24 h, the score was 1.16±1.29 and severity was close to "very weak" (Fig 3) .
The recovery rate from acute phase in patients treated with carperitide monotherapy was assessed in groups stratified by baseline characteristics. The recovery rate was significantly lower in patients with vs without acute myo- Table 3 ).
To assess the predictors of response to carperitide monotherapy, the efficacy of this agent was analyzed in patients stratified into 4 categories according to the criteria of Nohria et al. 13 Under this system, patients were classified based on the presence or absence of congestion as evidenced by peripheral edema and elevated jugular venous pressure and of low perfusion as evidenced by cold legs among physical findings described in case report forms.
Among patients in these 4 categories, the recovery rate from the acute phase of heart failure using carperitide monotherapy, as well as that in those who did not recover following carperitide monotherapy and were subsequently treated with either an inotropic agent or a vasodilator are summarized in Fig 4. As can be seen in the figure, 88.4% of subjects were "wet" cases. Although the recovery rate among patients receiving carperitide monotherapy in the dry and cold category was lower than that in the other 3 categories, a statistically significant difference was detected among the recovery rates of these 4 categories (p=0.005).
Among subjects who did not recover from the acute phase using carperitide monotherapy, an inotropic agent was concomitantly used or replaced in 14.3-42.6% and a vasodilator in 16.9-47.1%.
Within one month after infusion of carperitide therapy, 1,342 of 1,832 patients (73.3%) were discharged from hospital. In all, 71 (3.9%) patients died within 1 month after infusion with carperitide. The rate of discharge from hospital was higher in the 1,524 patients who recovered from the acute phase following carperitide monotherapy compared with the 308 patients who did not (77.7% vs 51.3%, respectively) and in those who recovered from the acute phase mortality was also lower (1.7% vs 14.6%, respectively).
ADRs
ADRs associated with carperitide were reported in 85 patients (4.64%); the most frequently reported ADR was hypotension (65 patients, 3.55%). Severe ADRs were reported in 13 patients (14 episodes, 0.71%): hypotension (3 episodes); acute myocardial infarction (2); heart failure (2); ventricular tachycardia (2); renal failure (2); cerebral infarction (1); hypovolemic shock (1); and acute renal failure (1).
Analysis of the incidence of ADRs in patients stratified using baseline characteristics revealed no significant difference according to sex, age range, NYHA functional classification, blood pressure and LVEF. The incidence of ADRs was significantly lower in patients who were complicated by hypertensive heart disease and renal disease, and in those with hemoglobin ≤12 g/dl than in their respective counterparts (Table 4) .
Discussion
Baseline Characteristics of Patients and Recovery From Acute Phase by Carperitide
The majority of patients enrolled in the present study had valvular heart disease (31.6%), hypertensive heart disease (29.3%), old myocardial infarction (22.3%) or cardiomyopathy (15.7%) as underlying disease. Mean LVEF was 45.5%, implying that many patients in the present study had preserved systolic function. Patients with acute myocardial infarction as the underlying disease accounted for 4.3% of enrolled subjects, which is lower than the 20-25% reported among those entered in the study conducted by Suwa et al and in the EuroHeart Failure Survey. 11, 14 In general, patients with acute myocardial infarction are treated with a continuous infusion of a nitrate to induce coronary vasodilation immediately upon hospitalization. In the present study, patients receiving continuous infusion of a therapeutic agent for acute myocardial infarction prior to carperitide were excluded; thus very few if any patients with acute myocardial infarction as the underlying cardiovascular disease were enrolled.
The present study revealed that the rate of recovery from the acute phase is negatively influenced by the severity of heart failure defined according to the NYHA or Killip classification, reduction of renal function and elevation of CRP levels. It is easily understandable that an increase in cardiac output is necessary in patients with severe heart failure and reduced renal function.
The analyzed subjects in the present study were retrospectively classified into 4 categories described by Nohria et al based on peripheral edema, elevated jugular venous pressure and cold legs. 13 Since dry-warm patients may be considered not to have any symptoms of either congestion or hypoperfusion, they responded to carperitide monotherapy better than those in the other categories (Fig 4) .
Thus it should be expected from the present results that approximately 10-25% patients will not recover from the acute phase using carperitide monotherapy regardless of the presence or absence of congestion and adequate perfusion, and that non-responders should be treated with either an inotropic agent or vasodilator. 13 The number indicated inside the ellipsoids represents the recovery rate of patients from acute phase of heart failure by carperitide monotherapy. Parenthesis indicates no. of patients. The ratios who were concomitantly treated with inotropics or vasodilator among patients who did not recover from acute phase due to poor response to carperitide monotherapy are also represented behind "inotropics" and "vasodilator" in each category. Significant difference was noted in the recovery rate of carperitide monotherapy among the 4 categories (p=0.005). 
Therapeutic Effect on Dyspnea
In the present study, the degree of dyspnea was assessed using the modified Borg scale. This scale is a tool used to assess patients by interviewing for subjective symptoms, and also to assess respiratory disease according to a scale of 0-10. To date, there has been reported no large-scale study in which dyspnea in AHFS patients was assessed by this tool. In the present study, it is believed that carperitide decreased preload by its vasodilator action and thereby significantly improved dyspnea as assessed using the modified Borg scale after treatment for 2 h. Saito et al reported that continuous intravenous infusion of carperitide in patients with NYHA class III-IV chronic heart failure significantly decreased right atrial pressure and pulmonary capillary wedge pressure within 30 min after the start of treatment. 15 Therefore it is considered that carperitide rapidly improves dyspnea through a rapid decrease in preload due to the venodilator action.
Excessive Decrease of Blood Pressure
Hypotension associated with carperitide may be caused by strong development of vasodilator and diuretic actions, the primary actions of this drug. In the "real world" of carperitide therapy, the incidence of hypotension was 9.45%, and a higher incidence was reported in elderly patients aged >65 years and in those with acute myocardial infarction as the underlying disease and LVEF <35%. 11 In contrast, in the present study mean SBP was 151.1±25.7 mmHg at baseline, only a small number of patients had underlying acute myocardial infarction, and the mean LVEF was 45.5±17.3%. Thus the incidence of hypotension was only 3.55% in the present study. This is to say, in patients with rather high initial blood pressure with pulmonary congestion and preserved cardiac function, carperitide seems to exert better safety and efficacy. Furthermore, the initial dose used in the present study was 0.025-0.05 g·kg -1 ·min -1 in half the patients (50.4%), which is lower than the conventionally used dosage. This observation may have reflected the low overall incidence of ADRs observed in the present study.
Pharmacological Characteristics of Carperitide as Vasodilator
Guidelines for the treatment of acute heart failure published by the Japanese Circulation Society and by the European Society of Cardiology recommend use of vasodilators as initial treatment rather than inotropic agents that potentially damage cardiomyocytes in AHFS patients in whom adequate fluid volume and blood pressure are preserved. 3, 4 A typical vasodilator used for the treatment of AHFS is nitrate. Differing from nitrates, carperitide inhibits the RAA and sympathetic nervous systems, which are believed related to the development, sustenance and progression of heart failure. 16, 17 Therefore carperitide might be a drug that has a mechanism of action related to the pathology of AHFS. It has been reported that patients who take nitrates might develop tolerance when these agents are used over the long term. 18 In contrast, it has been reported that the vasodilator effect of carperitide is maintained for 1 week without development of tolerance. 10 
Study Limitations
The present study has at least 3 limitations. First, this is an observation study with no control group, meaning that the effectiveness of carperitide could not be discriminated from that of vasodilators. Second, since the present study was an observational, non-interventional study, the criteria for discontinuing carperitide, combining other therapeutic agents with carperitide, and determining recovery from the acute phase of heart failure were determined by individual investigators. Third, the effects of carperitide on renal function, which is of concern when using nesiritide (hBNP), were not assessed in the present study because renal function parameters were not measured over time after the start of treatment. 19, 20 Further studies of carperitide as a first-line drug are warranted to investigate its effects on renal function.
The present study assessed the usefulness of carperitide according to the procedures and treatments recommended in guidelines for the treatment of acute heart failure. Despite being an observation study, this is the largest multicenter study yet conducted in AHFS patients in Japan. We believe that the results will be helpful -and indeed may be a compass -for the treatment of AHFS.
